Institute for Healthcare Delivery Science

Medicine & Life Sciences

1. Arthroplasty 100%
2. Knee Replacement Arthroplasties 63%
3. Hip 50%
4. Databases 49%
5. Survival 46%
6. Joints 45%
7. Odds Ratio 45%
8. Opioid Analgesics 44%
9. Confidence Intervals 44%
10. Costs and Cost Analysis 42%
11. Neoplasms 41%
12. Population 39%
13. Proteogenomics 38%
14. Anesthesia 31%
15. Length of Stay 28%
16. Cohort Studies 28%
17. Delivery of Health Care 28%
18. Therapeutics 27%
19. Comorbidity 27%
20. Inpatients 27%
21. Machine Learning 26%
22. Retrospective Studies 25%
23. Cost-Benefit Analysis 25%
24. Drug Therapy 24%
25. Patient Readmission 24%
26. Nerve Block 24%
27. Radiotherapy 24%
28. Multiple Myeloma 22%
29. Health 22%
30. Pandemics 22%
31. Mortality 21%
32. Peripheral Nerves 20%
33. Logistic Models 19%
34. Tacrine 19%
35. Patient Reported Outcome Measures 19%
36. Shoulder 19%
37. Breast Neoplasms 19%
38. Graft vs Host Disease 18%
39. Cisplatin 18%
40. Hospitalization 18%
41. Biomarkers 18%
42. Elderly 18%
43. Spine 18%
44. Type 2 Diabetes Mellitus 18%
45. Urinary Bladder Neoplasms 17%
46. Surgeons 17%
47. Obstructive Sleep Apnea 16%
48. Delirium 16%
49. Polycythemia Vera 16%
50. Prostatic Neoplasms 16%
51. INCB018424 15%
52. Telemedicine 15%
53. Safety 14%
54. Proteomics 14%
55. Ambulatory Surgical Procedures 14%
56. Medicare 14%
57. Acetaminophen 14%
58. Inflammatory Bowel Diseases 14%
59. Insurance 14%
60. Conduction Anesthesia 13%
61. Epilepsy 13%
62. Health Care Costs 13%
63. Hepatocellular Carcinoma 13%
64. Prescriptions 13%
65. Orthopedic Procedures 13%
66. Child 13%
67. Carcinoma 13%
68. Quality-Adjusted Life Years 13%
69. Cognition 13%
70. Recurrence 12%
71. Pediatrics 12%
72. Meta-Analysis 12%
73. Tibia 12%
74. Incidence 12%
75. Tranexamic Acid 12%
76. Health Expenditures 12%
77. Demography 11%
78. Blood Transfusion 11%
79. Pain Management 11%
80. Enhanced Recovery After Surgery 11%
81. Arthrodesis 11%
82. Radiation 11%
83. Patient Care 11%
84. Propensity Score 11%
85. Hip Fractures 11%
86. Observational Studies 11%
87. Primary Myelofibrosis 11%
88. Replacement Arthroplasties 11%
89. Lead 11%
90. Renal Cell Carcinoma 10%
91. Dementia 10%
92. Systematic Reviews 10%
93. Orthopedics 10%
94. Interviews 10%
95. Progression-Free Survival 10%
96. Depression 10%
97. Clinical Trials 10%
98. Cognitive Dysfunction 10%
99. Guidelines 10%
100. Fluorescence 10%